Search research articles
Contact Us
Filters
Showing results (31-40 of 49) with videos related to
Page
of 5
Sort By:
Cytotherapy
|
December 11, 2017
Systemic recovery and therapeutic effects of transplanted allogenic and xenogenic mesenchymal stromal cells in a rat blunt chest trauma model
Elisa Maria Amann, Markus Thomas Rojewski, Sinja Rodi, et al.
Cytotherapy
|
March 31, 2019
Translation of a standardized manufacturing protocol for mesenchymal stromal cells: A systematic comparison of validation and manufacturing data
Markus Thomas Rojewski, Ramin Lotfi, Cecilie Gjerde, et al.
Science (New York, N.Y.)
|
January 25, 2014
Endothelial cell-derived angiopoietin-2 controls liver regeneration as a spatiotemporal rheostat
Junhao Hu, Kshitij Srivastava, Matthias Wieland, et al.
Cytotherapy
|
February 3, 2012
Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components
Natalie Fekete, Mélanie Gadelorge, Daniel Fürst, et al.
Mabs
|
February 12, 2016
Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2
Werner Scheuer, Markus Thomas, Petra Hanke, et al.
Journal of the Royal Society, Interface
|
August 21, 2015
An integrated approach to quantitative modelling in angiogenesis research
Anthony J Connor, Radosław P Nowak, Erica Lorenzon, et al.
Plos One
|
April 25, 2013
Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain
Sebastian Fenn, Christian B Schiller, Julia J Griese, et al.
Plos One
|
February 14, 2013
A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors
Markus Thomas, Yvonne Kienast, Werner Scheuer, et al.
British Journal of Cancer
|
August 17, 2016
Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling
Lauren C J Baker, Jessica K R Boult, Markus Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy
Yvonne Kienast, Christian Klein, Werner Scheuer, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 49) with videos related to
Sort By:
Page
of 5
Cytotherapy
|
December 11, 2017
Systemic recovery and therapeutic effects of transplanted allogenic and xenogenic mesenchymal stromal cells in a rat blunt chest trauma model
Elisa Maria Amann, Markus Thomas Rojewski, Sinja Rodi, et al.
Cytotherapy
|
March 31, 2019
Translation of a standardized manufacturing protocol for mesenchymal stromal cells: A systematic comparison of validation and manufacturing data
Markus Thomas Rojewski, Ramin Lotfi, Cecilie Gjerde, et al.
Science (New York, N.Y.)
|
January 25, 2014
Endothelial cell-derived angiopoietin-2 controls liver regeneration as a spatiotemporal rheostat
Junhao Hu, Kshitij Srivastava, Matthias Wieland, et al.
Cytotherapy
|
February 3, 2012
Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components
Natalie Fekete, Mélanie Gadelorge, Daniel Fürst, et al.
Mabs
|
February 12, 2016
Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2
Werner Scheuer, Markus Thomas, Petra Hanke, et al.
Journal of the Royal Society, Interface
|
August 21, 2015
An integrated approach to quantitative modelling in angiogenesis research
Anthony J Connor, Radosław P Nowak, Erica Lorenzon, et al.
Plos One
|
April 25, 2013
Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain
Sebastian Fenn, Christian B Schiller, Julia J Griese, et al.
Plos One
|
February 14, 2013
A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors
Markus Thomas, Yvonne Kienast, Werner Scheuer, et al.
British Journal of Cancer
|
August 17, 2016
Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling
Lauren C J Baker, Jessica K R Boult, Markus Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy
Yvonne Kienast, Christian Klein, Werner Scheuer, et al.
Page
of 5